[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL183973A0 - Spm 927 for add -on therapy of schizophrenia - Google Patents

Spm 927 for add -on therapy of schizophrenia

Info

Publication number
IL183973A0
IL183973A0 IL183973A IL18397307A IL183973A0 IL 183973 A0 IL183973 A0 IL 183973A0 IL 183973 A IL183973 A IL 183973A IL 18397307 A IL18397307 A IL 18397307A IL 183973 A0 IL183973 A0 IL 183973A0
Authority
IL
Israel
Prior art keywords
spm
schizophrenia
therapy
add
Prior art date
Application number
IL183973A
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of IL183973A0 publication Critical patent/IL183973A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL183973A 2005-01-28 2007-06-14 Spm 927 for add -on therapy of schizophrenia IL183973A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia
PCT/EP2006/000722 WO2006079547A2 (en) 2005-01-28 2006-01-27 Spm 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
IL183973A0 true IL183973A0 (en) 2008-12-29

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183973A IL183973A0 (en) 2005-01-28 2007-06-14 Spm 927 for add -on therapy of schizophrenia

Country Status (12)

Country Link
EP (1) EP1841417A2 (en)
JP (1) JP2008528532A (en)
KR (1) KR20070096058A (en)
AR (1) AR057643A1 (en)
AU (1) AU2006208630B2 (en)
BR (1) BRPI0607043A2 (en)
CA (1) CA2595330A1 (en)
EA (1) EA015566B1 (en)
IL (1) IL183973A0 (en)
MX (1) MX2007009070A (en)
NO (1) NO20074361L (en)
WO (1) WO2006079547A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2037965B1 (en) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (en) * 2006-06-15 2014-03-12 优时比制药有限公司 Pharmaceutical composition with synergistic anticonvulsant effect
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
EP3766485A1 (en) 2010-12-02 2021-01-20 UCB Pharma GmbH Once daily formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
RU2764443C2 (en) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Transdermal therapeutic system containing azenapine and polysiloxane or polyisobutylene
AU2017384526B2 (en) 2016-12-20 2023-11-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN110799180A (en) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 Transdermal therapeutic system containing asenapine and siloxane acrylic hybrid polymer
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112704672A (en) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
BR112021024380A2 (en) 2019-06-04 2022-04-19 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DK1243262T3 (en) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hitherto unknown use of a peptide class of compounds to treat non-neuropathic inflammatory pain
EP1243263B1 (en) 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain

Also Published As

Publication number Publication date
EA015566B1 (en) 2011-10-31
JP2008528532A (en) 2008-07-31
NO20074361L (en) 2007-10-26
KR20070096058A (en) 2007-10-01
BRPI0607043A2 (en) 2009-08-04
WO2006079547A3 (en) 2006-09-21
AU2006208630B2 (en) 2011-09-29
CA2595330A1 (en) 2006-08-03
WO2006079547A2 (en) 2006-08-03
AU2006208630A1 (en) 2006-08-03
AR057643A1 (en) 2007-12-12
MX2007009070A (en) 2007-09-12
EA200701594A1 (en) 2008-02-28
EP1841417A2 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
IL183973A0 (en) Spm 927 for add -on therapy of schizophrenia
HK1199874A1 (en) Spiro-oxindole compounds and their uses as therapeutic agents
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
IL190390A0 (en) Modified 4'-nucleosides as antiviral agents
EP2063889A4 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
HK1119577A1 (en) Compounds for the treatment of metabolic disorders
ZA200809857B (en) Terphenyl derivatives for treatment of alzheimer's disease
EP1758854A4 (en) Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EP1809601A4 (en) Compounds for alzheimer's disease
IL180513A0 (en) Process for synthesis of 4-4'-diamino-diphenyl-sulfone
ZA200902808B (en) An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure
EP1807396A4 (en) 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
EP1955698A4 (en) Preventive/therapeutic agent for alzheimer's dementia
HK1097831A1 (en) Benzopyran compounds useful for the treatment of arrhytmia
GB0400802D0 (en) Compounds for the treatment of disease
ZA200804266B (en) Therapeutic uses of steroidal compounds
ZA200606780B (en) Compounds for the treatment of diseases
EP1598355A4 (en) Therapeutic agent for schizophrenia
IL191749A0 (en) Propionamide compounds as antiinflammatory agents
ZAA200501616S (en) " an article of bedlinen "
PL373686A1 (en) Method for manufacture of 4'-hydroxyflavone
GB0425064D0 (en) Compounds useful for the treatment of diseases
AP2006003743A0 (en) Compounds useful for the treatment of diseases